![GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP ‘‘Fluorodopa F 18 Injection’’](https://sim.maxiran.com/images/files/0168648-L-542829902.jpg)
GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP ‘‘Fluorodopa F 18 Injection’’
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Chih-Hao K. Kao Wen-Lin Hsu Heng-Li Xie Ming-Chi Lin Wen-Chun Lan Hao-Yu Chao
- چاپ و سال / کشور: 2011
Description
Introduction Lately, 6-[18F]fluoro-L-DOPA (FDOPA) has found increase in its clinical demand for whole-body positron emission tomography (PET) scans, and two key issues in fulfilling this demand are the difficulties in producing FDOPA under the recently imposed PET drug good manufacturing practice (GMP) regulations and in providing it in the quality meeting the terms of major compendia. This paper describes the approaches for the GMP production of FDOPA and for the product testing to meet the standard of United States Pharmacopeia (USP) ‘‘Fluorodopa F 18 Injection.’’ Methods FDOPA was produced by the carrier-added electrophilic aromatic substitution reaction in the facility complying Pharmaceutical Inspection Cooperation Scheme clean room standard. The special aseptic handling technique was applied to minimize the bioburden. The product quality control followed all testing items and procedures, including three different settings of HPLC. Results The process yielded FDOPA average 2.60 ± 0.26 GBq (N = 22) in every batch. All qualities of the product were within the specifications described in the USP ‘‘Fluorodopa F 18 Injection.’’ The entire production was audited by the government authority and certified to comply with the latest PET drug GMP regulation. Conclusion Our efforts in producing FDOPA following all aspects of GMP requirements have resulted in a product with the USP quality and certified as GMP complied. The routine production yields enough doses for three to four whole-body scans in each batch. The issues discussed in the report provide good reference for producers planning in routine production for PET drugs that are not commonly produced or with complicated compendial quality control tests.
Ann Nucl Med (2011) 25:309–316 DOI 10.1007/s12149-010-0463-x Received: 9 August 2010 / Accepted: 15 December 2010 / Published online: 23 February 2011
